Phase 2 obesity trial (NEJM 2023) The landmark study published in the New England Journal of Medicine tested retatrutide in adults with obesity over 48 weeks
Exposure to xenobiotics, heavy metals (such as lead, mercury and arsenic), stress, poor dietary choices, toxic cocktails of prescription and non-prescription drugs, trauma and infections all have huge consequences for the body and its ability to maintain adequate glutathione levels
Furthermore, increased healthcare expenditure, demand for innovative therapies, growing awareness for early detection and diagnosis, supportive government initiatives and regulatory frameworks, access to expert healthcare professionals and, the proven efficacy and safety of GLP-1 receptor agonists for managing blood sugar and promoting weight loss are the factors fuelling the market dominance of this segment
Colleen Berg is a project manager in NCSLs Health Program.
We included randomised controlled trials from peer reviewed articles and excluded conference abstracts and non-English literature
